Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesRacial differences in primary central nervous system lymphoma incidence and survival rates
Neuro-Oncology, 06/12/09
Pulido JS et al. - Incidence for ages over 49 years for Whites was twice that for Blacks. Survival at 12 months, 24 months, and 60 months was higher among Whites than Blacks. Research is needed to determine the origin of these differences.
Related Articles
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial
The Lancet, 11/05/09
Relevance Score: 70%
When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type
Annals of Oncology, 10/29/09
Relevance Score: 67%
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status
Journal of Neuro-Oncology, 10/27/09
Relevance Score: 67%
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
Annals of Oncology, 10/30/09
Relevance Score: 66%
Treatment options for central nervous system lymphomas in immunocompetent patients
Expert Review of Neurotherapeutics, 10/23/09
Relevance Score: 65%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique
Neurosurgical Focus, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/17/09
Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma
Journal of Neuro-Oncology, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor